Press release: closing of Lovaltech seed financing round
Funding has been allocated to conduct Phase 1 and 2 clinical trials of LVT-001.
Lovaltech has closed a seed funding round of €6.8 million. This comprises €1.5 million in equity and €5.3 million in non-dilutive financing from Bpifrance, which was obtained through a France 2030 project funding call. The main investors are Da Vinci Labs, a deep-tech incubator based in Touraine, and the Centre-Val de Loire Seed Fund, which is managed by UI Investissement.
This funding will enable the launch of Phase 1 and 2 clinical trials for LVT-001, the first vaccine from our LVT-NEXUS platform.
Designated as “Deeptech” company by Bpifrance, Lovaltech holds an exclusive worldwide licence for the patent on its first vaccine, granted by its original research institutions.